ECE2017 Eposter Presentations: Adrenal and Neuroendocrine Tumours Endocrine tumours and neoplasia (50 abstracts)
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) followed in the endocrinology and nutrition service’s monographic outpatient clinics of neuroendocrine tumors in hospital clínico san carlos (HCSC). Description of its characteristics and evolution
Ines Jimenez-Varas 1 , Angela Amengual 1 , Rona Penso 1 , Anna Ortolá 2 , Ane Azkutia 1 , Lorea Herraiz 1 , Paz de Miguel 1 & Jose Angel Díaz 1
1Hospital Clinico San Carlos, Madrid, Spain; 2Hospital Clinico Universitario, Valladolid, Spain.
Introduction: The multidisciplinary approach of the patients with GEP-NETs is very important, having a fundamental role the participation of the endocrinologist.
Methods: Description of cases of GEP-NETs followed in the Service of Endocrinology of the SCCH from 1990 to 2016.
Results: 95 patients were included, 53.7% were males, age 61.2 years (IR: 50.5–73.5). The diagnosis was incidental in 53.8%. 27.6% presented clinical secretion, from them the most frequent was carcinoid (13.8%). The median primary tumor size was 3 cm (IR: 2–4). The most frequent location was pancreas (43.2%) followed by small intestine (20%). The initial stage was 49.5% I and 39.6% IV (72% hepatic metastases). Clinic as a cause of diagnosis was significantly associated with staging (Cramer’s V (V) 0.72, P<0.05). Chromogranin A (CrA) was high in 30% and 5-Hydroxyindolacetic in 18.7% (only 73.7 and 58.4%, respectively) were studied. 9.4% of the patients had history of familiar syndrome. Degree of differentiation (DD) 1 and 2 (63 and 30.3%) predominated. The follow-up was 6.63 years (IR: 4.6–9.3). During that period, 30.2% of the cases were lost, with mortality rate of 17.9% of the remaining group, due to progression in 83.3% of the patients. The most frequently used treatment was surgery (39.1%). From stage IV patients 20.8% received only somatostatin analogues and 45% received more than one treatment (surgery, chemotherapy, antiangiogenic drugs, somatostatin analogues or everolimus) There was significant association between mortality and stage (V 0.42, P 0.04), CrA (V 0.38, P 0.012), presence of symptoms at diagnosis (V 0.32, P 0.017) and DD (V 0.41, P 0.02).
Conclusion: Patients followed in the endocrinology outpatients clinic are more frequently stages I and DD1 and DD2 that have been incidentally diagnosed. More than 50% of the cases were treated only with surgery or somatostatin analogues. One third of the patients had secretion.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more